News

The application for traditional approval includes 48-week data from two Phase III studies known as Duet-1 and Duet-2. Intelence is currently marketed in the US by Tibotec Therapeutics,

Tigris in-licensed the exclusive worldwide rights to GGTI-2418 from Yale University and the University of South Florida. Edmundo Muniz, president and CEO of Tigris, said: The filing of

Under the terms of the agreement, entered into in December 2005, the companies are collaborating to discover and develop novel Nanobody-based therapeutics against disease targets that are difficult

hPAM4 is a humanized monoclonal antibody targeting an epitope in the MUC1 antigen expressed in most pancreatic cancer, but not pancreatitis, normal pancreas or most other normal tissues.

Medicis markets Solodyn for the treatment of moderate-to-severe acne. Impax and Medicis have previously entered into a settlement and license agreement, under which Impax has a license to

Under the terms of this agreement, RXi has the option, at its sole discretion, to sell to YA Global Investments newly issued common shares, subject to certain conditions,

The study is a randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, tolerability and efficacy of daily TT-223 treatments for 12 weeks with a six-month follow-up. Approximately

Approximately 48 healthy volunteers participated in the study, with 16 recruited for each of three dose groups. In each dose group, 12 volunteers received a single dose of

The primary objectives of this safety and tolerability study have been achieved. These were to determine the maximum tolerated dose and the dose-limiting toxicities for the agent when